Orphan designation: Plerixafor Treatment of acute respiratory distress syndrome (ARDS), 19/02/2024 Positive
Overview
- Overview
This medicine was designated as an orphan medicine for the treatment of acute respiratory distress syndrome on 19 February 2024. - Orphan designation does not mean the medicine is available or authorised for use.
- All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
- EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: